Press reviews
2025-10-27
What if physical exercise were the key to clearing “chemo brain” after breast cancer?
Oncology
By Lila Rouland | Published October 27, 2025 | 3 min read
Breast cancer, affecting more than 2.3 million women each year, often leads to lasting aftereffects well beyond treatment. Among them, cancer-related cognitive impairment (CRCI) affects up to 70% of patients, with symptoms such as memory loss, difficulty concentrating, and mental slowing—often described as “chemo brain.” Eve...
Breast cancer, affecting more than 2.3 million women each year, often leads to lasting aftereffects well beyond treatment. Among them, cancer-related cognitive impairment (CRCI) affects up to 70% of patients, with symptoms such as memory loss, difficulty concentrating, and mental slowing—often described as “chemo brain.” Eve...
Read more
By Ana Espino | Published on october 27, 2025 | 3 min read
Although breast cancer is being treated more and more effectively, it often leaves significant physical aftereffects following surgery: chronic pain, upper-limb lymphedema, loss of mobility, and persistent fatigue. These symptoms directly affect quality of life and the return to independence. Yet, functional rehabilitat...
Although breast cancer is being treated more and more effectively, it often leaves significant physical aftereffects following surgery: chronic pain, upper-limb lymphedema, loss of mobility, and persistent fatigue. These symptoms directly affect quality of life and the return to independence. Yet, functional rehabilitat...
Read more
By Ana Espino | Published on october 24, 2025 | 3 min read
Breast cancer is the most common malignancy among women worldwide. Despite major therapeutic advances, a substantial proportion of patients remain at risk of relapse, particularly those with residual disease after neoadjuvant therapy. Residual disease is a strong prognostic factor for early recurrence, especially in agg...
Breast cancer is the most common malignancy among women worldwide. Despite major therapeutic advances, a substantial proportion of patients remain at risk of relapse, particularly those with residual disease after neoadjuvant therapy. Residual disease is a strong prognostic factor for early recurrence, especially in agg...
Read more
By Carolina Lima | Published October 23, 2025 | 3 min read
In recent years, mental health care has undergone a significant transformation, with digital tools reshaping how therapy is delivered. Among these innovations, virtual cognitive behavioral therapy (eCBT) has emerged as a promising alternative to traditional in-person therapy, offering flexibility, accessibility, and compara...
In recent years, mental health care has undergone a significant transformation, with digital tools reshaping how therapy is delivered. Among these innovations, virtual cognitive behavioral therapy (eCBT) has emerged as a promising alternative to traditional in-person therapy, offering flexibility, accessibility, and compara...
Read more
By Ana Espino | Published on october 23, 2025 | 3 min read
Brain metastases are a frequent and severe complication of advanced cancers, particularly non–small cell lung cancer (NSCLC) and metastatic breast cancer (MBC). They significantly worsen prognosis and quality of life, while remaining difficult to manage due to the blood–brain barrier (BBB), which limits the penetration...
Brain metastases are a frequent and severe complication of advanced cancers, particularly non–small cell lung cancer (NSCLC) and metastatic breast cancer (MBC). They significantly worsen prognosis and quality of life, while remaining difficult to manage due to the blood–brain barrier (BBB), which limits the penetration...
Read more
By Lila Rouland | Published October 22, 2025 | 3 min read
Triple-negative breast cancer (TNBC) is characterized by the absence of hormonal receptors (ER, PR) and the HER2 protein. This particularity significantly limits targeted therapeutic options, leading to a poor prognosis marked by high recurrence and low overall survival rates. Given the biological heterogeneity of TNBC, global...
Triple-negative breast cancer (TNBC) is characterized by the absence of hormonal receptors (ER, PR) and the HER2 protein. This particularity significantly limits targeted therapeutic options, leading to a poor prognosis marked by high recurrence and low overall survival rates. Given the biological heterogeneity of TNBC, global...
Read more
By Ana Espino | Published on october 22, 2025 | 3 min read
Triple-negative breast cancer (TNBC), characterized by the absence of hormonal receptors and HER2 expression, accounts for approximately 15–20% of all breast cancer cases. It is associated with a high risk of recurrence and early metastasis. Among patients who present with residual invasive disease after neoadjuvant ch...
Triple-negative breast cancer (TNBC), characterized by the absence of hormonal receptors and HER2 expression, accounts for approximately 15–20% of all breast cancer cases. It is associated with a high risk of recurrence and early metastasis. Among patients who present with residual invasive disease after neoadjuvant ch...
Read more
By Ana Espino | Published on october 21, 2025 | 4 min read
Triple-negative breast cancer (TNBC) is a particularly aggressive form of cancer, characterized by the absence of hormone receptors (ER/PR) and HER2. It primarily affects younger women, progresses rapidly, and carries a high risk of relapse, especially due to the lack of exploitable therapeutic targets. Currently, chemo...
Triple-negative breast cancer (TNBC) is a particularly aggressive form of cancer, characterized by the absence of hormone receptors (ER/PR) and HER2. It primarily affects younger women, progresses rapidly, and carries a high risk of relapse, especially due to the lack of exploitable therapeutic targets. Currently, chemo...
Read more
2025-10-21
Oncology
By Lila Rouland | Published October 21, 2025 | 3 min read
Triple-negative breast cancer (TNBC), lacking hormonal and HER2 receptors, represents an aggressive and heterogeneous subtype. Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have recently shown therapeutic potential; however, only about 20% of metastatic patients respond to monotherapy. This highlights the urgent...
Triple-negative breast cancer (TNBC), lacking hormonal and HER2 receptors, represents an aggressive and heterogeneous subtype. Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have recently shown therapeutic potential; however, only about 20% of metastatic patients respond to monotherapy. This highlights the urgent...
Read more
By Ana Espino | Published on october 20, 2025 | 3 min read
The synchronous development of several primary cancers is a rare but increasingly observed phenomenon, particularly in patients carrying genetic mutations such as BRCA1. In this particular case, the coexistence of triple-negative breast cancer and rectal adenocarcinoma is all the more complex as it may occur in patient...
The synchronous development of several primary cancers is a rare but increasingly observed phenomenon, particularly in patients carrying genetic mutations such as BRCA1. In this particular case, the coexistence of triple-negative breast cancer and rectal adenocarcinoma is all the more complex as it may occur in patient...
Read more
By Carolina Lima | Published October 17, 2025 | 3 min read
Breast cancer screening is a cornerstone of early detection, but for women with dense breast tissue, traditional mammography often falls short. To address this challenge, the Breast Screening—Risk Adapted Imaging for Density (BRAID) trial, recently published in The Lancet, offers promising evidence on whether supplemen...
Breast cancer screening is a cornerstone of early detection, but for women with dense breast tissue, traditional mammography often falls short. To address this challenge, the Breast Screening—Risk Adapted Imaging for Density (BRAID) trial, recently published in The Lancet, offers promising evidence on whether supplemen...
Read more
By Ana Espino | Published on october 17, 2025 | 3 min read
Metastatic HR+/HER2– breast cancer — the most common subtype in postmenopausal women — remains an incurable disease despite advances in endocrine therapy and CDK4/6 inhibitors. Most patients eventually develop secondary resistance, limiting therapeutic options. Alterations in the PI3K/AKT/PTEN pathway, frequently observ...
Metastatic HR+/HER2– breast cancer — the most common subtype in postmenopausal women — remains an incurable disease despite advances in endocrine therapy and CDK4/6 inhibitors. Most patients eventually develop secondary resistance, limiting therapeutic options. Alterations in the PI3K/AKT/PTEN pathway, frequently observ...
Read more
By Ana Espino | Published on october 16, 2025 | 2 min read
Metastatic breast cancer (MBC) remains an incurable disease with highly heterogeneous clinical forms. Despite recent advances, standard treatments—hormone therapy, chemotherapy, and immunotherapy—have limitations in the face of secondary resistance, genetic variability of tumors, and the progressive exhaustion of thera...
Metastatic breast cancer (MBC) remains an incurable disease with highly heterogeneous clinical forms. Despite recent advances, standard treatments—hormone therapy, chemotherapy, and immunotherapy—have limitations in the face of secondary resistance, genetic variability of tumors, and the progressive exhaustion of thera...
Read more
By Lila Rouland | Published October 16, 2025 | 3 min read
Metastatic breast cancer relies heavily on amino acids for its growth and survival. These essential nutrients can be synthesized or absorbed directly from circulating serum, making them an attractive metabolic target. While enzymatic inhibition of amino acid biosynthetic pathways has shown limited success in clinical settings...
Metastatic breast cancer relies heavily on amino acids for its growth and survival. These essential nutrients can be synthesized or absorbed directly from circulating serum, making them an attractive metabolic target. While enzymatic inhibition of amino acid biosynthetic pathways has shown limited success in clinical settings...
Read more
By Ana Espino | Published on october 15, 2025 | 2 min read
Metastatic breast cancer (MBC) represents the most advanced stage of the disease and remains incurable despite major therapeutic progress. It is responsible for the majority of breast cancer–related deaths. Current treatments—hormone therapy, chemotherapy, and immunotherapy—extend survival but do not eliminate the disea...
Metastatic breast cancer (MBC) represents the most advanced stage of the disease and remains incurable despite major therapeutic progress. It is responsible for the majority of breast cancer–related deaths. Current treatments—hormone therapy, chemotherapy, and immunotherapy—extend survival but do not eliminate the disea...
Read more
